Technology | November 19, 2012

Hologic’s best-in-class solutions for breast screening, intervention and treatment, osteoporosis risk assessment and extremity imaging highlight its commitment to putting Patients First

3D mammography (breast tomosynthesis) system

U.S. Food and Drug Administration (FDA) in February 2011 and has been available in countries recognizing the CE mark since 2008. Hologic’s 3D mammography technology is available in 46 states and 29 countries outside the U.S.

Hologic’s 3D mammography system placed first in the digital mammography category in the KLAS 2012 annual survey of healthcare executives and clinicians. 3D mammography was recently selected by AuntMinnie as the “hottest clinical procedure” of the year for the third year in a row. AuntMinnie is the largest and most comprehensive community Web site for medical imaging professionals worldwide. In October, the Cleveland Clinic picked 3D mammography as one of the Top 10 Medical Innovations for 2013 at the Clinic's 10th annual Medical Innovation Summit.

Fifteen of the clinical papers and over 50 of the workshops, seminars, poster sessions and scientific papers to be presented at the conference are on 3D mammography (breast tomosynthesis).  Clinical presentations cover the use of tomosynthesis in screening and diagnostic applications.

Hologic is once again offering RSNA meeting attendees sixteen 75-minute sessions with hands-on experience reading 3D breast tomosynthesis images in combination with conventional and synthesized 2D images. Brief lectures will provide an overview of the technologies prior to the hands-on sessions. Each program will be taught by a leading breast imaging radiologist.  Conference attendees can register to take a workshop through the RSNA meeting web site.

Some of Hologic’s other advances in breast tomosynthesis on display at the conference include its tomosynthesis biopsy option for use with the Affirm™ biopsy guidance system and its C-View™ synthesized 2D image option. The tomosynthesis biopsy option is CE marked and is pending FDA clearance. The C-View Synthesized 2D image option received CE marking in 2011 and received a favorable vote for approval from an FDA Advisory Panel in October 2012. 

For more information: www.hologic.com


Related Content

News | FDA

Dec. 8, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, has submitted a 510(k) premarket ...

Time December 08, 2025
arrow
News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
Subscribe Now